Gordon Saul has more than 15 years' start-up and business development experience in the pharmaceutical and medical device areas. Saul currently holds operating roles in three InterWest portfolio companies, including Diatos (CBO), Carbylan BioSurgery (CBO/CFO), and RadioRx (CEO).

Earlier at InterWest, Saul was on the founding team at AlgoRx Pharmaceuticals (ANSV), holding both CFO and chief business officer roles. Prior to joining InterWest, he was a co-founder, board member and senior vice president of business development & marketing for PowderJect Pharmaceuticals plc, a publicly-traded drug delivery company acquired by Chiron Corporation in 2003. Prior to PowderJect, he held business development roles at ALZA Corporation and Advanced Cardiovascular Systems, a division of Guidant Corp.

Saul has also worked in Japan in the financial services industry and in management consulting for The Boston Consulting Group. He holds an engineering degree from Dartmouth College and an M.B.A. from Stanford University.